Abstract:Background Uveal melanoma (UM) is the most common primary intraocular malignancy in adults. It has been demonstrated that microRNA-145 (miR-145) is correlated with the progression of various cancers by regulating the expression of multiple target genes, especially a number of genes that regulate angiogenesis and proliferation. However, the underlying mechanisms of miR-145 in tumor angiogenesis of UM are still not well illustrated. Thus, we aimed to explore the potential target genes or pathways regulated by miR-145 in UM and the effect of miR-145 on invasion and angiogenesis. Methods Totally, 24 choroid samples were collected in our study, including 12 UM samples and 12 normal uveal tissues. The expression of neuroblastoma RAS viral oncogene homolog (N-RAS), phosphorylated protein kinase B (p-AKT), and vascular endothelial growth factor (VEGF) in UM tissues and normal uveal tissues was analyzed using Western blotting analysis. Lentivirus expression system was used to construct MUM-2B and OCM-1 cell lines with stable overexpression of miR-145. Transwell and endothelial cell tube formation assay were used to measure the effects of miR-145 on the invasion and angiogenesis of UMin vitro. The downstream target genes of miR-145 were predicted by bioinformatics and confirmed using a luciferase assay. BALB/c nude mice models were established to investigate the mechanisms of miR-145 on tumor growth and angiogenesisin vivo. Group data comparisons were performed using analysis of Student'sttest. A two-tailedP Results The results of Western blotting analysis indicated that the expressions of N-RAS (1.10 +/- 0.35vs.0.41 +/- 0.36,t = 3.997,P = 0.012), p-AKT (1.16 +/- 0.22vs.0.57 +/- 0.03,t = 7.05,P = 0.001), and VEGF (0.97 +/- 0.32vs.0.45 +/- 0.21,t = 3.314,P = 0.008) in UM tumor tissues were significantly higher than those in normal uveal tissue. Luciferase assay demonstrated N-RAS and VEGF as downstream targets of miR-145. Moreover, tube formation assay revealed that miR-145-transfected human microvascular endothelial cell line formed shorter tube length (36.10 +/- 1.51 mmvs.42.91 +/- 0.94 mm,t = 6.603,P = 0.003) and less branch points (350.00 +/- 19.97vs.406.67 +/- 17.62,t = 3.685,P = 0.021) as compared with controls. In addition, the numbers of invaded MUM-2B and OCM-1 cells with miR-145 overexpression were significantly lower than the controls (35.7 +/- 3.3vs.279.1 +/- 4.9,t = 273.75,P vs.95.6 +/- 4.7,t = 21.27,P < 0.001, respectively).In vivo, xenografts expressing miR-145 had smaller sizes (miR-145vs.miR-scr, 717.41 +/- 502.62 mm(3)vs.1694.80 +/- 904.33 mm(3),t = 2.314,P = 0.045) and lower weights (miR-145vs.miR-scr, 0.74 +/- 0.46 gvs.1.65 +/- 0.85 g,t = 2.295,P = 0.045). Conclusion Our results indicated that miR-145 is an important tumor suppressor and the inhibitory strategies against N-RAS/VEGF signaling pathway might be potential therapeutic applications for UM in the future.

Inhibition of CD146 Lessens Uveal Melanoma Progression Through Reducing Angiogenesis and Vasculogenic Mimicry.

Cd146 Is A Coreceptor For Vegfr-2 In Tumor Angiogenesis

Erratum to: CD146 as a promising therapeutic target for retinal and choroidal neovascularization diseases

Impaired tumor angiogenesis and VEGF-induced pathway in endothelial CD146 knockout mice

Inhibition of tumor angiogenesis and melanoma growth by targeting vascular E-selectin

MicroRNA-145 suppresses uveal melanoma angiogenesis and growth by targeting neuroblastoma RAS viral oncogene homolog and vascular endothelial growth factor.

A Small Interfering CD147-Targeting RNA Inhibited the Proliferation, Invasiveness, and Metastatic Activity of Malignant Melanoma

Soluble CD146 cooperates with VEGF-A to generate an immunosuppressive microenvironment in CD146-positive tumors: interest of a combined antibody-based therapy

Effects of Oncogenic Gαq and Gα11 Inhibition by FR900359 in Uveal Melanoma

MicroRNA 329 suppresses angiogenesis by targeting CD146.

Inhibition of tumor growth and vasculogenic mimicry by cucumin through downregulation of the EphA2/PI3K/MMP pathway in a murine choroidal melanoma model

miR-142-3p suppresses uveal melanoma by targeting CDC25C, TGFβR1, GNAQ, WASL, and RAC1

miR-142-3p suppresses uveal melanoma by targeting CDC25C, TGF beta R1, GNAQ, WASL, and RAC1

Therapeutic Effects of Anti-CD90 Monoclonal Antibody in Melanoma

Structure basis for AA98 inhibition on the activation of endothelial cells mediated by CD146

The Multi-Kinase Inhibitor Afatinib Serves As a Novel Candidate for the Treatment of Human Uveal Melanoma

Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer

APRPG-modified Nanoliposome Loaded with Mir-146A-5p Inhibitor Suppressed Choroidal Neovascularization by Targeting Endothelial Cells.

Hypoxia-inducible factor 1 upregulation of both VEGF and ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma

VEGF Induce Vasculogenic Mimicry of Choroidal Melanoma through the PI3k Signal Pathway

CM082, a Novel VEGF Receptor Tyrosine Kinase Inhibitor, Can Inhibit Angiogenesis in Vitro and in Vivo.